Today, we take a look at a small biopharma stock that might be on the cusp of a turnaround. Being a shareholder in BioDelivery Sciences has required a lot of patience over the past year, to say the least.
However, it does appear the stock has or is in the process of putting in a bottom. More importantly, 2017 is shaping up to be an inflection point that the market seems unaware of based on where the stock is currently trading.
